Review
Biochemistry & Molecular Biology
Anna Kubicka, Karolina Matczak, Magdalena Labieniec-Watala
Summary: The differences in metabolism between cancer cells and normal cells lead to increased proliferation and abnormal differentiation of cancer cells, while the focus of anti-cancer therapy development is on reprogramming cellular metabolic pathways to halt uncontrolled proliferation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Biochemistry & Molecular Biology
John J. Lemasters
Summary: In post-mitotic cells, mitochondrial ATP/ADP exchange occurs via adenine nucleotide translocator (ANT), while cancer cells predominantly utilize non-electrogenic ATP-Mg/phosphate carrier for the exchange, leading to decreased cytosolic ATP/ADP levels. These alterations promote aerobic glycolysis and confer specific growth advantages to cancer cells.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS
(2021)
Article
Biochemistry & Molecular Biology
Zhikun Li, Mei Geng, Xiaojian Ye, Yunhan Ji, Yifan Li, Xiangyang Zhang, Wei Xu
Summary: This study reveals that IRF7 is downregulated in osteosarcoma and its higher expression is associated with a better survival prognosis. IRF7 plays critical roles in suppressing aerobic glycolysis in osteosarcoma cells through inhibition of PKM2 expression, making it a potential therapeutic target for osteosarcoma patients.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2022)
Article
Multidisciplinary Sciences
V. F. E. D. Smolders, C. Rodriguez, I Blanco, R. Szulcek, Wim Timens, L. Piccari, Y. Roger, X. Hu, Constanza Moren, C. Bonjoch, L. Sebastian, M. Castella, J. Osorio, V. Peinado, Harm Jan Bogaard, P. H. A. Quax, M. Cascante, J. A. Barbera, O. Tura-Ceide
Summary: This study compares the metabolic characteristics of endothelial cells from patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH), and finds differences between them, suggesting different disease pathology and treatment mechanisms.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Irene Bagaloni, Axel Visani, Sara Biagiotti, Annamaria Ruzzo, Mohsen Navari, Maryam Etebari, Lucia Mundo, Massimo Granai, Stefano Lazzi, Alessandro Isidori, Federica Loscocco, Jiejin Li, Lorenzo Leoncini, Giuseppe Visani, Mauro Magnani, Pier Paolo Piccaluga
Summary: The study revealed enhanced glucose metabolism in most lymphoma subtypes, with a general shift to aerobic glycolysis. Not only aggressive lymphomas, but also indolent ones like marginal zone lymphomas, showed this phenomenon. Metformin was shown to induce cell death in BL cells by affecting cellular metabolism.
FRONTIERS IN ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Komal Tyagi, Supratim Mandal, Adhiraj Roy
Summary: Epithelial ovarian cancer, a deadly gynecological malignancy that is often diagnosed at advanced stages, displays resistance to standard chemotherapeutic regimens. Recent studies have shown that the 'Warburg effect', where ovarian cancer cells consume glucose via glycolysis even in aerobic conditions, contributes significantly to disease progression and chemoresistance, making it a potential novel drug target for intervention.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2021)
Article
Cell Biology
Cheng Peng, Sheng-Tao Hou, Chu-Xia Deng, Yandong Zhang
Summary: In this study, it was revealed that DHX33 plays a critical role in the Warburg effect of cancer cells by altering local epigenetic marks to promote the transcription of glycolysis genes, ultimately leading to cancer cell proliferation. The study highlights the significance of RNA helicase DHX33 in the Warburg effect and cancer therapeutics.
JOURNAL OF CELLULAR PHYSIOLOGY
(2021)
Review
Oncology
D. Grahame Hardie
Summary: Otto Warburg published the first paper on the Warburg effect in 1923, revealing the difference in lactate production between tumor tissues and normal tissues in glucose metabolism. However, the mechanisms underlying the Warburg effect are still not fully understood to this day.
ENDOCRINE-RELATED CANCER
(2022)
Article
Critical Care Medicine
Zhiguo Su, Hu Jiao, Jincai Fan, Liqiang Liu, Jia Tian, Cheng Gan, Zengjie Yang, Tiran Zhang, Yihua Chen
Summary: Keloid fibroblasts (KFs) exhibit a metabolic characteristic known as the Warburg effect, which is distinct from other types of scars or the proliferative stage of scars. KFs show increased expression of key glycolytic enzymes, higher glucose consumption, and lactate production. However, this phenomenon was not observed in atrophic scar fibroblasts (ASFs), proliferative stage scar fibroblasts (PSSFs), or hypertrophic scar fibroblasts (HSFs). Treatment with the glycolysis inhibitor 2-deoxy-D-glucose (2-DG) reduced cell viability in KFs. Keloids have unique energy metabolism compared to other types of scars.
Letter
Oncology
Yi Xu, Christopher Hino, David J. Baylink, Jeffrey Xiao, Mark E. Reeves, Jiang F. Zhong, Saied Mirshahidi, Huynh Cao
Summary: This study demonstrates the successful use of vitamin D gene therapy to treat AML mouse models. The researchers found that 1,25VD3 treatment affected the expression of 17,757 genes, with a significant increase in fructose-bisphosphatase 1 (FBP1) expression. Additionally, 1,25VD3 was found to regulate various metabolic processes in AML. The results suggest that targeting FBP1 overexpression induced by 1,25VD3 could be a novel therapeutic approach to reduce energy production in AML blasts.
BIOMARKER RESEARCH
(2022)
Review
Oncology
Adrian Casas-Benito, Sonia Martinez-Herrero, Alfredo Martinez
Summary: Approximately a century ago, Otto Warburg discovered that cancer cells use a different metabolism called aerobic glycolysis or the Warburg effect. This metabolism allows cancer cells to produce more ATP and promotes cancer progression. Succinate, a Krebs cycle intermediate, has been found to have protumoral functions in cancer and could be a potential target for cancer therapy. However, further research is needed to explore its potential in cancer prevention and treatment.
Article
Biochemistry & Molecular Biology
Lijiang Ji, Weixing Shen, Feng Zhang, Jie Qian, Jie Jiang, Liping Weng, Jiani Tan, Liu Li, Yugen Chen, Haibo Cheng, Dongdong Sun
Summary: The study found that worenine can affect the glucose metabolism and glycolysis of colorectal cancer cells, with anti-cancer effects and the ability to reverse the Warburg effect. The results suggest that worenine may target HIF-1 alpha to inhibit the growth and proliferation of colorectal cancer cells.
CELLULAR & MOLECULAR BIOLOGY LETTERS
(2021)
Article
Medicine, Research & Experimental
Kausik Bishayee, Uddin Md. Nazim, Vijay Kumar, Jieun Kang, Jaebong Kim, Sung-Oh Huh, Ali Sadra
Summary: In MYCN-amplified neuroblastoma, treatment with the HDAC inhibitor vorinostat leads to a reprogramming of the glycolytic pathway, increasing fatty acid oxidation and oxidative phosphorylation. This reprogramming is correlated with reduced levels of MYCN and increased levels of PPARD transcription factors. Additionally, the combination of HDAC and mTORC1 inhibitors increases reactive oxygen species levels. The glycolytic enzymes HK2 and GPI are most affected by this combination. Overall, this combination treatment shows promising results without causing significant toxicity in mice.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Medicine, Research & Experimental
Hong Zhang, Xiaoyang Su, Stephen K. Burley, X. F. Steven Zheng
Summary: This study reveals the molecular mechanism by which mTOR promotes the "Warburg Effect" in HCC, which is important for the metabolism and development of HCC, as well as the anticancer response of mTOR-targeted therapy.
Review
Chemistry, Medicinal
Ioana-Ecaterina Pralea, Alina-Maria Petrache, Adrian Bogdan Tigu, Diana Gulei, Radu-Cristian Moldovan, Maria Ilies, Raul Nicoara, Simona-Codruta Heghes, Alina Uifalean, Cristina-Adela Iuga
Summary: The complex nature of cancer poses many challenges, but plant-derived compounds show promise in anticancer therapy. This review provides an overview of how these compounds can affect tumor glycolysis and HIF-1 pathways, emphasizing the importance of cell culture-based metabolomics in understanding the response of cancer cells to phytochemicals.
Article
Gastroenterology & Hepatology
Claire Boyer, David Sefrioui, Romain Cohen, Romain Chautard, Marine Perrier, Hugo Lebrun, Gael Goujon, Vincent Hautefeuille, Marie Dior, Thomas Walter, Florence Mary, Silvain Manfredi, Francois-Xavier Caroli-Bosc, Baptiste Cervantes, Romain Coriat, Elise Deluche, Aziz Zaanan, Raphael Olivier, Olivier Bouche, Guillaume Piessen, Thierry Lecomte, Christophe Louvet, Pierre Michel, Thomas Aparicio, Thierry Andre, Julien Taieb, Violaine Randrian, David Tougeron
Summary: This French multicenter study evaluated the overall survival of patients with dMMR/MSI digestive non-colorectal tumors. The results showed that most tumors were oesophago-gastric or small bowel adenocarcinomas and were at a localized stage at diagnosis. Patients with localized tumors and R0 resection had a median overall survival of 134.0 +/- 64.2 months. Overall, dMMR/MSI digestive non-colorectal tumors have a good prognosis, but advanced tumors treated with standard chemotherapy have a poor prognosis.
DIGESTIVE AND LIVER DISEASE
(2023)
Article
Oncology
Victoire Dabout, Christelle de la Fouchardiere, Thibault Voron, Thierry Andre, Florence Huguet, Romain Cohen
Summary: Gastric cancer is one of the most common cancers worldwide, and it can be divided into two groups: gastroesophageal junction adenocarcinomas and distal gastric adenocarcinomas. The treatment strategies for these cancers differ, with multimodal therapy for gastroesophageal junction adenocarcinomas and surgery and peri-operative chemotherapy for gastric adenocarcinomas. There is currently no evidence to support the superiority of one treatment strategy over the other. Nivolumab has recently been validated as an adjuvant therapy for esophageal cancer patients who have residual tumor after preoperative chemoradiotherapy. Adjuvant chemoradiotherapy or chemotherapy may be considered on a case-by-case basis for patients without preoperative treatment.
BULLETIN DU CANCER
(2023)
Article
Gastroenterology & Hepatology
Maximilien Heran, Florence Renaud, Christophe Louvet, Guillaume Piessen, Thibault Voron, Marine Lefevre, Olivier Dubreuil, Thierry Andre, Magali Svrcek, Romain Cohen
Summary: Histological response to neoadjuvant chemotherapy (NAC) in localized dMMR gastric/OGJ adenocarcinoma is not significantly different compared to pMMR tumors. This study provides additional data for the discussion of avoiding NAC in patients with dMMR gastric/OGJ adenocarcinomas.
DIGESTIVE AND LIVER DISEASE
(2023)
Article
Oncology
Thierry Andre, David Tougeron, Guillaume Piessen, Christelle de la Fouchardiere, Christophe Louvet, Antoine Adenis, Marine Jary, Christophe Tournigand, Thomas Aparicio, Jerome Desrame, Astrid Lievre, Marie-Line Garcia-Larnicol, Thomas Pudlarz, Romain Cohen, Salome Memmi, Dewi Vernerey, Julie Henriques, Jeremie H. Lefevre, Magali Svrcek
Summary: The NEONIPIGA study found that perioperative platinum-based chemotherapy is the standard treatment for resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma. However, the efficacy of perioperative chemotherapy in gastric/GEJ adenocarcinoma with deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) remains debatable. This study showed that neoadjuvant nivolumab-based therapy is feasible, associated with no unexpected toxicity, and has a high pathological complete response (pCR) rate in patients with dMMR/MSI-H resectable gastric/GEJ adenocarcinoma.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Gastroenterology & Hepatology
Solenn Barraud, David Tougeron, Laurent Villeneuve, Clarisse Eveno, Arnaud Bayle, Yann Parc, Marc Pocard, Thierry Andre, Romain Cohen
Summary: This study evaluated the prognosis of patients with isolated peritoneal carcinomatosis (PC) from MSI/dMMR metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors. The results demonstrated long-term benefit of immune checkpoint inhibitors for patients with isolated PC from MSI/dMMR mCRC, making it the best therapeutic option. However, the value of surgery for residual lesions remains unknown.
DIGESTIVE AND LIVER DISEASE
(2023)
Article
Oncology
Ofer Margalit, William S. Harmsen, Einat Shacham-Shmueli, Molly M. Voss, Ben Boursi, Anna D. Wagner, Romain Cohen, Curtis L. Olswold, Leonard B. Saltz, Daniel A. Goldstein, Herbert Hurwitz, Niall C. Tebbutt, Fairooz F. Kabbinavar, Richard A. Adams, Benoist Chibaudel, Axel Grothey, Takayuki Yoshino, John Zalcberg, Aimery de Gramont, Qian Shi, Heinz-Josef Lenz
Summary: In this study, data from 3369 patients with metastatic colorectal carcinoma were analyzed to investigate the sex-specific response to bevacizumab. The results showed that bevacizumab improved overall survival in both males and females, although the benefit was less significant in females. Stratified analysis based on age revealed that females under the age of 60 did not experience a survival benefit from bevacizumab.
EUROPEAN JOURNAL OF CANCER
(2023)
Editorial Material
Oncology
Romain Cohen
BULLETIN DU CANCER
(2023)
Article
Oncology
Eleonore Spitzer, Pascale Cervera, Thierry Andre, Romain Cohen
Summary: This article introduces the innovations related to HER2 (Human Epidermal Growth Factor Receptor 2) overexpression in metastatic colorectal cancer (mCRC), which mainly affects 2 to 5% of CRC located in the distal colon and rectum. The diagnosis is based on immunohistochemistry, in situ hybridization, and molecular biology. HER2 overexpression predicts resistance to EGFR-targeted treatments and is associated with poor prognosis and higher risk of brain metastasis. Several therapeutic combinations targeting HER2 have been evaluated in phase II trials with significant objective response rates. Despite the lack of marketing authorization, the systematic evaluation of HER2 status is recommended.
BULLETIN DU CANCER
(2023)
Article
Oncology
Jean-Baptiste Bachet, Pierre Laurent-Puig, Aurelia Meurisse, Olivier Bouche, Leo Mas, Valerie Taly, Romain Cohen, Jean-Marc Gornet, Pascal Artru, Samy Louafi, Anne Thirot-Bidault, Isabelle Baumgaertner, Romain Coriat, David Tougeron, Thierry Lecomte, Florence Mary, Thomas Aparicio, Lysiane Marthey, Helene Blons, Dewy Vernerey, Julien Taieb
Summary: Circulating tumor DNA (ctDNA) is a potential prognostic marker in metastatic colorectal cancer (mCRC) patients. This study found that ctDNA detection can predict overall survival, and the optimal cut-off value for ctDNA mutated allelic frequency is 20%.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Koen Zwart, Frederieke H. van Der Baan, Romain Cohen, Thomas Aparicio, Christelle de la Fouchardiere, Thierry Lecomte, Cornelis J. A. Punt, David Sefrioui, Rik J. Verheijden, Geraldine R. Vink, G. Emerens Wensink, Aziz Zaanan, Miriam Koopman, David Tougeron, Jeanine M. L. Roodhart
Summary: Current knowledge on prognostic biomarkers in metastatic colorectal cancer (mCRC) is mainly based on mCRC patients with pMMR tumors. It is uncertain whether these biomarkers have the same prognostic value in mCRC patients with dMMR tumors.
Article
Oncology
Giovanni Randon, Yu Aoki, Romain Cohen, Leonardo Provenzano, Vincenzo Nasca, Samuel J. Klempner, Steven B. Maron, Riccardo Cerantola, Joseph Chao, Lorenzo Fornaro, Walter Ferrari Bravo, Filippo Ghelardi, Margherita Ambrosini, Paolo Manca, Massimiliano Salati, Akihito Kawazoe, Valerie Zhu, Darren Cowzer, Virginia Genovesi, Sara Lonardi, Kohei Shitara, Thierry Andre, Filippo Pietrantonio
Summary: This study found that immune checkpoint inhibitor-based therapy is superior to chemotherapy in patients with dMMR and/or MSI-high advanced gastric or gastroesophageal junction adenocarcinoma. However, more studies are needed to examine prognostic features within this patient population.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
E. Alouani, M. Mercier, C. Flecchia, E. Auclin, A. Hollebecque, T. Mazard, A. Turpin, S. Pernot, R. Cohen, M. Dutherage, S. Kim, F. Sclafani, M. Ben-Abdelghani, C. Herve, T. Aparicio, C. De La Fouchardiere, G. Perkins, V. Hautefeuille, M. Jaffrelot, C. Gallois, V. Bongard, D. Tougeron, J. Taieb, R. Guimbaud
Summary: This multicenter retrospective study confirms the efficacy and safety of immunotherapy in patients with advanced MMRd/MSI CRC and identifies markers associated with long-term benefit.
Editorial Material
Oncology
Thierry Andre, Romain Cohen
JCO ONCOLOGY PRACTICE
(2023)
Article
Oncology
Pauline Marolleau, David Tougeron, Benoit Allignet, Romain Cohen, David Sefrioui, Blandine Gallet, Frederic Dumont, Rosine Guimbaud, Emily Alouani, Guillaume Passot, Gregoire Desolneux, Francois Ghiringhelli, Frederic Marchal, Farouk Mourthadhoi, Romain Coriat, Romain Desgrippes, Christophe Locher, Gael Goujon, Gaetan Des Guetz, Thomas Aparicio, Etienne Paubelle, Aurelien Dupre, Christelle de la Fouchardiere
Summary: Our study aimed to describe metastasectomy results, characterize histological response, and evaluate pathological complete response (pCR) rate in patients with dMMR/MSI mCRC. We retrospectively reviewed data from all consecutive patients with dMMR/MSI mCRC who underwent surgical metastasectomy between January 2010 and June 2021 in 17 French centers. The primary outcome was to assess the pCR rate defined by tumor regression grade (TRG) 0.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Letter
Oncology
Romain Cohen, Thierry Andre, Jeremie H. Lefevre
JOURNAL OF CLINICAL ONCOLOGY
(2023)
